Officials from the International Serious Adverse Events Consortium (iSAEC) recently announced a partnership with the HMO Research Network to help identify genetic markers for serious drug-related adverse events, which will use electronic health records (EHR) to exchange information.
Participating members of the HMO Research Network will use EHRs to compare the genetic and clinic data from derived cases to healthy control groups. Officials said that the goal is to identify mutations that are associated with specific serious drug-related adverse events.
This collaboration represents a need for individuals who hold health information technology management degrees. These professionals can help hospitals and research companies install an information exchange that allows medical facilities to transfer health records.
“By working with these nine leading HMOs, all of which have sophisticated EMRs and outstanding clinical research capabilities, we hope to open up a new, more scalable research channel to enroll subjects into this vital research,” said Arthur L. Holden, chairman of the iSAEC.
They added that the collaboration using EHRs is expected to last 20 months, and that the iSAEC will use the HMO Research Network’s centralized clinical data warehouses.